PeerView | Gynaecology/Obstetrics

Free CME from PeerView

Gynecology/Obstetrics CME

PVI, PeerView Institute for Medical Education

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

Linda Ahn, MSN, ANP-BC, AOCNP

April 27, 2022

Medical Learning Institute, Inc.

Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer

Bhavana Pothuri, MD, MS

April 27, 2022

PVI, PeerView Institute for Medical Education

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

Prof. Solange Peters, MD, PhD

April 09, 2022

Medical Learning Institute, Inc.

Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier Settings

Henry M. Kuerer, MD, PhD, FACS

April 07, 2022

PVI, PeerView Institute for Medical Education

Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations

Elizabeth Eaman, MD

April 01, 2022

Medical Learning Institute, Inc.

Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

Kurt A. Schalper, MD, PhD

March 22, 2022

Medical Learning Institute, Inc.

When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum

Bradley J. Monk, MD, FACS, FACOG

March 21, 2022

Pages